



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/557,997

04/24/2000

Ganesh Venkataraman

M0656.70055US00

7686

23628 7590 07/01/2008
WOLF GREENFIELD & SACKS, P.C.
600 ATLANTIC AVENUE
BOSTON, MA 02210-2206

EXAMINER

SMITH, CAROLYN L

ART UNIT

PAPER NUMBER

1631

MAIL DATE

DELIVERY MODE

07/01/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Response to Rule 312 Communication	Application No.	Applicant(s)
	09/557,997	VENKATARAMAN ET AL.
	Examiner	Art Unit
	Carolyn L. Smith	1631

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. ☒ The amendment filed on 18 June 2008 under 37 CFR 1.312 has been considered, and has been:

a) ☐ entered.

b) ☐ entered as directed to matters of form not affecting the scope of the invention.

c) ☐ disapproved because the amendment was filed after the payment of the issue fee.

Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.

d) ☐ disapproved. See explanation below.

e) ☒ entered in part. See explanation below.

The amendment to claim 37 has been entered. It is a minor grammatical change that does not change the scope of the claim.

The amendment to claim 54 has been entered. It is a minor grammatical change that does not change the scope of the claim.

The amendment to claim 73 has not been entered, because the deletion of "heparin-like glycosaminoglycan" and replacing it with "polysaccharide" was ALREADY made in the Examiner's Amendment, mailed 4/8/08. It is noted that the last two lines of claim 73 defines "heparin-like glycosaminoglycan" as described in the specification on page 12, lines 25-27. Therefore, the scope of the claim has not changed.

/Marjorie Moran/
Supervisory Patent Examiner, Art Unit 1631

/Carolyn L Smith/
Primary Examiner, Art Unit 1631
6/26/08